Cellyan Biotechnology Co., Ltd
HKPDNASDAQHealthcareMedical - Distribution
Previous close
$0.4087
−$0.0003 · -0.07%
HKPD company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
65
Undervalued
Momentum
19
Strong Down
Sentiment
51
Mixed
Risk resilience
15
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.
- Industry
- Medical - Distribution
- Sector
- Healthcare
- Headquarters
- HK
- CEO
- Chenyu Liang
- Listed since
- Jan 15, 2025
- Employees
- 27
Market position
Day range
Current $0.4087
52-week range
Current $0.4087
- Open
- $0.3999
- Previous close
- $0.409
- Volume
- 120.71K
- 0.2× average
- Average volume
- 599.81K
- Average daily volume
- Market cap
- 4.49M USD
- Beta
- 2.33
- Market reference 1
- 50-day average
- $0.4075
- +0.29% above average
- 200-day average
- $0.655
- -37.61% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 0 USD
- P/E (TTM)
- -18.75×
- P/B (TTM)
- 2.86×
- P/S (TTM)
- 0.33×
- EV / EBITDA
- 0×
- Earnings yield
- 0.00%
- Free cash flow yield
- 0.00%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 10.32%
- Operating margin
- -7.41%
- Net margin
- -8.46%
- Return on equity
- 0.00%
- Return on assets
- 0.00%
- Return on invested capital
- 0.00%
Financial health
- Debt / equity
- 0.44×
- Current ratio
- 0×
- Altman Z-score
- 5.02
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 20.31M USD | 16.69M USD | 12.56M USD |
| Cost of goods sold | 17.9M USD | 13.13M USD | 9.82M USD |
| Gross profit | 2.42M USD | 3.56M USD | 2.74M USD |
| Selling, general, and administrative | 2.22M USD | 1.89M USD | 1.76M USD |
| Operating expenses | 2.28M USD | 1.95M USD | 1.7M USD |
| Interest income | 1.74K USD | 474 USD | 219 USD |
| Interest expense | 97.67K USD | 82.77K USD | 23.24K USD |
| Depreciation and amortization | 1.07M USD | 925.58K USD | 714.59K USD |
| Operating income | 132.04K USD | 1.61M USD | 1.04M USD |
| Net income | −27.06K USD | 1.33M USD | 998.2K USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -0.003
- FY2025 · -101.67% year over year
- Latest fiscal-year revenue
- 20.31M USD
- FY2025 · +21.72% year over year
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
HKPD news
HKPD peers
Continue in GoAI
Research HKPDresearch.disclaimer